Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 8, Issue 5, Pages 516-520Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.7b00018
Keywords
Bioisostere; bicyclo[1.1.1]pentane; BCP; resveratrol; pharmacokinetic studies
Categories
Ask authors/readers for more resources
Over the last few decades, resveratrol has gained significance due to its impressive array of biological activities; however, its true potential as a drug has been severely constrained by its poor bioavailability. Indeed, several studies have implicated this bioavailability trait as a major roadblock to resveratrol's potential clinical applications. To mitigate this pharmacokinetic issue, we envisioned a tactical bioisosteric modification of resveratrol to bicyclo[1.1.1]-pentane (BCP) resveratrol. Relying on the beneficial bioisosteric potential demonstrated by the BCP-scaffold, we hypothesized that BCP resveratrol would have an inherently better in vivo PK profile as compared to its natural counterpart. To validate such a hypothesis, it was necessary to secure a synthetic access to this novel structure. Herein we describe the first synthesis of BCP-resveratrol and disclose its PK properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available